Literature DB >> 17785553

Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers.

Wennuan Liu1, Bao-Li Chang, Scott Cramer, Patrick P Koty, Tao Li, Jishan Sun, Aubrey R Turner, Chris Von Kap-Herr, Peggy Bobby, Jianyu Rao, S Lilly Zheng, William B Isaacs, Jianfeng Xu.   

Abstract

PURPOSE: Chromosome 6q14-21 is commonly deleted in prostate cancers, occurring in approximately 22% of all tumors and approximately 40% of metastatic tumors. However, candidate prostate tumor suppressor genes in this region have not been identified, in part due to the large and broad nature of the deleted region implicated in previous studies. EXPERIMENTAL
DESIGN: We first used high-resolution Affymetrix single nucleotide polymorphism arrays to examine DNA from malignant and matched nonmalignant cells from 55 prostate cancer patients. We identified a small consensus region on 6q14-21 and evaluated the deletion status within the region among additional 40 tumors and normal pairs using quantitative PCR and fluorescence in situ hybridization. We finally tested the association between the deletion and Gleason score using the Fisher's exact test.
RESULTS: Tumors with small, interstitial deletions at 6q14-21 defined an 817-kb consensus region that is affected in 20 of 21 tumors. The MAP3K7 gene is one of five genes located in this region. In total, MAP3K7 was deleted in 32% of 95 tumors. Importantly, deletion of MAP3K7 was highly associated with higher-grade disease, occurring in 61% of tumors with Gleason score >or=8 compared with only 22% of tumors with Gleason score <or=7. The difference was highly significant (P = 0.001).
CONCLUSION: Our study provides strong evidence for the first time that a small deletion at 6q15, including the MAP3K7 gene and four other genes, is associated with high-grade prostate cancers. Although the deletion may be a marker for high-grade prostate cancer, additional studies are needed to understand its molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785553     DOI: 10.1158/1078-0432.CCR-07-0300

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  32 in total

1.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

Review 2.  Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Adv Anat Pathol       Date:  2008-11       Impact factor: 3.875

Review 3.  TAK1 regulates hepatic cell survival and carcinogenesis.

Authors:  Yoon Seok Roh; Jingyi Song; Ekihiro Seki
Journal:  J Gastroenterol       Date:  2014-01-21       Impact factor: 7.527

4.  Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer.

Authors:  W Liu; J Lindberg; G Sui; J Luo; L Egevad; T Li; C Xie; M Wan; S-T Kim; Z Wang; A R Turner; Z Zhang; J Feng; Y Yan; J Sun; G S Bova; C M Ewing; G Yan; M Gielzak; S D Cramer; R L Vessella; S L Zheng; H Grönberg; W B Isaacs; J Xu
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

5.  GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP).

Authors:  Zongli Xu; Jeannette T Bensen; Gary J Smith; James L Mohler; Jack A Taylor
Journal:  Prostate       Date:  2010-11-17       Impact factor: 4.104

6.  Suppression of Tak1 promotes prostate tumorigenesis.

Authors:  Min Wu; Lihong Shi; Adela Cimic; Lina Romero; Guangchao Sui; Cynthia J Lees; J Mark Cline; Darren F Seals; Joseph S Sirintrapun; Thomas P McCoy; Wennuan Liu; Jin Woo Kim; Gregory A Hawkins; Donna M Peehl; Jianfeng Xu; Scott D Cramer
Journal:  Cancer Res       Date:  2012-03-30       Impact factor: 12.701

7.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.

Authors:  Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong
Journal:  Hum Mol Genet       Date:  2008-01-17       Impact factor: 6.150

8.  Deregulation of an imprinted gene network in prostate cancer.

Authors:  Teodora Ribarska; Wolfgang Goering; Johanna Droop; Klaus-Marius Bastian; Marc Ingenwerth; Wolfgang A Schulz
Journal:  Epigenetics       Date:  2014-02-10       Impact factor: 4.528

9.  Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer.

Authors:  Yu Cheng; Jin Woo Kim; Wennuan Liu; Thomas A Dunn; Jun Luo; Matthew J Loza; Seong-Tae Kim; Siqun Lilly Zheng; Jianfeng Xu; William B Isaacs; Bao-Li Chang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

10.  Heterozygous Mutations in MAP3K7, Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome.

Authors:  Carine Le Goff; Curtis Rogers; Wilfried Le Goff; Graziella Pinto; Damien Bonnet; Maya Chrabieh; Olivier Alibeu; Patrick Nistchke; Arnold Munnich; Capucine Picard; Valérie Cormier-Daire
Journal:  Am J Hum Genet       Date:  2016-07-14       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.